Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease

Clinical Drug Investigation

Volumn 26, Issue 4, 2006, Pages 195-202

  Thaha, Mochammad ^a   Yogiantoro, Mohammad ^a   Tomino, Yasuhiko ^b  

^a AIRLANGGA UNIVERSITY   (Indonesia)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; HIDONAC; HOMOCYSTEINE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; URTICARIA;

ACETYLCYSTEINE; ADULT; AGED; BLOOD PRESSURE; BLOOD PROTEINS; DIABETIC NEPHROPATHIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HEMATOCRIT; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFUSIONS, INTRAVENOUS; KIDNEY CALCULI; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME; URTICARIA;

EID: 33645544935     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626040-00003     Document Type: Article

References (30)

1. Friedman AN, Bostom AG, Selhub J, et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12 (10): 2181-9
2. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10 (4): 891-900
3. Austen SK, Coombes JS, Fassett RG. Homocysteine and cardiovascular disease in renal disease. Nephrology (Carlton) 2003; 8 (6): 285-95
4. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97 (2): 138-41
5. Bachmann J, Tepel M, Raidt H, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6 (1): 121-5
6. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61 (2): 609-14
7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl. 3): S112-9
8. Coresh J, Longenecker JC, Miller III ER, et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 Suppl.): S24-30
9. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003; (85): S105-10
10. Perna AF, Ingrosso D, Satta E, et al. Metabolic consequences of hyperhomocysteinemia in uremia. Am J Kidney Dis 2001; 38 (4 Suppl. 1): S85-90
11. De Vriese AS, Verbeke F, Schrijvers BF, et al. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int 2002; 61 (4): 1199-209
12. Stam F, van Guldener C, Ter Wee PM, et al. Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease. Kidney Int 2005; 67 (1): 259-64
13. Ducloux D, Aboubakr A, Motte G, et al. Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant 2002; 17 (5): 865-70
14. Sunder-Plassmann G, Fodinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11 (6): 1106-16
15. Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107 (7): 992-5
16. Hultberg B, Andersson A, Masson P, et al. Plasma homocysteine and thiol compound fractions after oral administration of N-acetylcysteine. Scand J Clin Lab Invest 1994; 54 (6): 417-22
17. Ventura P, Panini R, Pasini MC, et al. N-Acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol Res 1999; 40 (4): 345-50
18. Wiklund O, Fager G, Andersson A, et al. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels. Atherosclerosis 1996; 119 (1): 99-106
19. Scholze A, Rinder C, Beige J, et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109 (3): 369-74
20. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4 (5): 1205-13
21. Van Tellingen A, Grooteman MP, Bartels PC, et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001; 59 (1): 342-7
22. Friedman AN, Bostom AG, Laliberty P, et al. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study. Am J Kidney Dis 2003; 41 (2): 442-6
23. Perna AF, Ingrosso D, Lombardi C, et al. Homocysteine in uremia. Am J Kidney Dis 2003; 41 (3 Suppl. 1): S123-6
24. Tozawa M, Iseki K, Iseki C, et al. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61 (2): 717-26
25. Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102 (20): 2479-83
26. Mendelsohn ME, O'Neill S, George D, et al. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 1990; 265 (31): 19028-34
27. Efrati S, Dishy V, Averbukh M, et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 2003; 64 (6): 2181-7
28. De Flora S, Izzotti A, D'Agostini F, et al. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Biol Chem 1996; 271 (7): 3667-70
29. Tsai JC, Jain M, Hsieh CM, et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem 1996; 271 (7): 3667-70
30. Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005; 67 (6): 2288-94